J Korean Diabetes.  2021 Jun;22(2):85-90. 10.4093/jkd.2021.22.2.85.

Recent Perspective of Metformin

• Hong S

• KMID: 2526185
• DOI: http://doi.org/10.4093/jkd.2021.22.2.85

Abstract

Metformin has been used clinically more than 60 years in type 2 diabetes as the first-line drug for treatment. Metformin has been prescribed in more than 80% of Korean patients with diabetes. Despite long-term use and wide prescription of metformin in patients with type 2 diabetes, many questions remain. Recent advances have revealed a new mechanism of action and new benefits of metformin. In this article, we review recent advances regarding metformin treatment.

Keyword

Cardiovascular diseases; Delayed-action preparations; Diabetes mellitus; type 2; Metformin

Reference

1. Bailey CJ. Metformin: historical overview. Diabetologia. 2017; 60:1566–76.

2. Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, et al. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019; 43:398–406.

3. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020. 43(Suppl 1):S98–110.

4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998. 352:854–65.

5. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995; 333:550–4.

6. Sansome DJ, Xie C, Veedfald S, Horowitz M, Rayner CK, Wu T. Mechanism of glucose-lowering by metformin in type 2 diabetes: role of bile acids. Diabetes Obes Metab. 2020; 22:141–8.

7. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; 30:359–71.

8. Scheen AJ. Will delayed release metformin provide better management of diabetes type 2? Expert Opin Pharmacother. 2016; 17:627–30.

9. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011; 50:81–98.

10. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008; 51:1552–3.

11. Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014; 9:e100778.

12. Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016; 39:198–205.

13. Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, et al. Improved glycemic control with minimal systemic metformin exposure: effects of metformin delayed-release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018; 13:e0203946.

14. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009; 169:616–25.

15. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, et al. SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013; 36:1304–11.

16. Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019; 18:96.

17. Zhang K, Yang W, Dai H, Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: results from meta-analysis. Diabetes Res Clin Pract. 2020; 160:108001.

18. Mohan M, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019; 40:3409–17.

19. Tseng CH. Metformin use is associated with a lower risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: a retrospective cohort analysis. J Am Heart Assoc. 2019; 8:e011640.

20. Richardson TL Jr, Hackstadt AJ, Hung AM, Greevy RA, Grijalva CG, Griffin MR, et al. Hospitalization for heart failure among patients with diabetes mellitus and reduced kidney function treated with metformin versus sulfonylureas: a retrospective cohort study. J Am Heart Assoc. 2021; doi: 10.1161/JAHA.120.019211. [Epub ahead of print].

21. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41:255–323.

22. Crowley MJ, Williams JW Jr, Kosinski AS, D'Alessio DA, Buse JB. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Care. 2017; 40:1787–9.

23. Inzucchi SE, Fitchett D, Jurišić-Eržen D, Woo V, Hantel S, Janista C, et al. EMPA-REG OUTCOME^® Investigators Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes Obes Metab. 2020; 22:631–9.

24. Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021; 23:29–38.

25. Zaccardi F, Kloecker DE, Buse JB, Mathieu C, Khunti K, Davies MJ. Use of metformin and cardiovascular effects of new classes of glucose-lowering agents: a meta-analysis of cardiovascular outcome trials in type 2 diabetes. Diabetes Care. 2021; 44:e32–4.